Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTAMIRA: acalabrutinib + rituximab in elderly patients with untreated mantle cell lymphoma
2023-509864-96-00Phase 2Authorised
- Sponsor
- Region Skåne
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib and rituximab in mantle cell lymphoma (MCL), sponsored by Region Skåne. Primary endpoint: Progression-free survival. Planned start Dec 2021; status: authorised.
02
Drugs
acalabrutinibrituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2023-509864-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509864-96-00.